Clinical Trials
15 trialsNCT07093086 2026-05-06
Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1 Withdrawn
NCT07049432 2026-04-01
CARMEN-803
University of Utah
Phase 1 Withdrawn
NCT04556266 2025-05-13
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Withdrawn
NCT06290622 2025-05-06
PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL
University of Alabama at Birmingham
Phase 1 Withdrawn
NCT04052061 2025-02-21
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
ImmunityBio, Inc.
Phase 1 Withdrawn
NCT04995536 2024-04-25
CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL
City of Hope Medical Center
Phase 1 Withdrawn
NCT05796271 2024-02-29
Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn
NCT05513612 2023-03-01
Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies
Shanghai Pudong Hospital
Phase 1 Withdrawn
NCT04877080 2023-02-10
CD19 and BCMA Targeted Fast Dual CAR-T for CD19+ Refractory/Relapsed B-NHL
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
Phase 1 Withdrawn
NCT04635683 2022-09-30
Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 1 Withdrawn
NCT03605589 2021-04-01
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
Children's Hospital Medical Center, Cincinnati
Phase 1 Withdrawn
NCT03920631 2021-03-23
MicroBLITZ
Duke University
Phase 1 Withdrawn
NCT03925428 2020-09-28
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT00210340 2015-03-30
A Phase I Study of Intrathecal Rituximab in Patients With Lymphomatous Meningitis
International Extranodal Lymphoma Study Group (IELSG)
Phase 1 Withdrawn
NCT00538096 2008-09-05
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
MedImmune LLC
Phase 1 Withdrawn